Viatris news
The WiseView Research desk's stories that name Viatris, the latest headlines about it, and the trades members of Congress and company insiders have disclosed. The VTRS page →
- HeadlineWill Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report?
- HeadlineWhy Viatris (VTRS) is a Top Momentum Stock for the Long-Term
- HeadlineHere's Why Viatris (VTRS) is a Strong Value Stock
- HeadlineViatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia
- HeadlineViatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
- HeadlineViatris to Buy Pacira BioSciences for $1.65 Billion
- HeadlineViatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
- HeadlineVTRS vs. AVTR: Which Stock Is the Better Value Option?
- HeadlineShould Value Investors Buy Viatris (VTRS) Stock?
- HeadlineViatris (VTRS) is a Top-Ranked Momentum Stock: Should You Buy?
- HeadlineViatris to Report Third-Quarter 2026 Financial Results on November 5, 2026
- HeadlineWhy Viatris (VTRS) is a Top Value Stock for the Long-Term
- HeadlineViatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year
- CongressJohn Fetterman sold $1,001 - $15,000 of VTRS
- CongressRob Bresnahan sold $1,001 - $15,000 of VTRS
- CongressGilbert Cisneros sold $1,001 - $15,000 of VTRS
- CongressRo Khanna bought $1,001 - $15,000 of VTRS
Headlines link to their publishers. Members of Congress disclose ranges, not exact amounts, and may file weeks after the trade; insider filings are open-market purchases and sales from SEC Form 4. For information only, not investment advice.